General MedicationsINTRAVITREALStandard
TRIESENCE
TRIAMCINOLONE ACETONIDE
Standard Dose
40MG/ML (40MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview TRIESENCE is listed in Drugs@FDA under application 022048 (NDA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient TRIAMCINOLONE ACETONIDE Form and strength INJECTABLE;INTRAVITREAL - 40MG/ML (40MG/ML) Sponsor HARROW EYE Submission history Latest submission status date: 2014-06-23 00:00:00.
Structured Monograph
Clinical summary
Approval overview TRIESENCE is listed in Drugs@FDA under application 022048 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient TRIAMCINOLONE ACETONIDE Form and strength INJECTABLE;INTRAVITREAL - 40MG/ML (40MG/ML) Sponsor HARROW EYE Submission history Latest submission status date: 2014-06-23 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.